Over 400 firms, including Cipla, Airtel & Tata Steel, to unveil Q4 results this week. Track key announcements and dividend…
Markets plunge as selling hits all sectors, with IT stocks and broader indices falling sharply. Track key losers and stay…
Pharma stocks fall as Nifty Pharma drops 3%. Sun Pharma, Cipla slide amid US tariff fears and export risk concerns.
Let’s take a look at 5 best CDMO pharma stocks in India.
Stocks to watch today, January 08: Track key stock updates, top deals, and performance movers in today’s market—see which companies…
Motilal Oswal has given Gland Pharma a ‘Buy’ rating with a Rs 2,310 target price, implying a 17% upside. The…
Nifty Pharma index drops over 2% after Trump unveils 100% tariff on drug imports – see which stocks are most…
Motilal Oswal tips L&T, Gland Pharma, and Kotak Bank for up to 18% returns—see why these stocks could boost your…
Stocks to watch today, May 21: GIFT Nifty indicates a subdued start for domestic indices. Here are top stocks to…
Gland Pharma posted a 3 per cent decline in consolidated net profit to Rs 186.54 crore in the fourth quarter…
According to IQVIA, the product had US sales of approximately USD 111.6 million for the twelve months ending December 2023.
Q1FY25 Results: The company also presented an outlook for Q2FY25 and said that lower activity levels are expected due to…
The Product has US sales of approximately $92 million for twelve months ending in February 2024, according to IQVIA.
Gland Pharma’s total expenses jumped nearly 89% to Rs 12.99 billion, dragged by a more than three-fold climb in its…
Gland Pharma shares hit the upper circuit today after the company’s revenue grew 41% on-year to Rs 1,208.6 crore in…
According to the company’s statement, core markets of US, Europe, Canada, Australia, and New Zealand accounted for 70% of revenue…
According to the company’s statement, its margin on earnings before interest, taxes, depreciation, and amortisation slipped to 35 percent from…
Gland Pharma’s Singapore subsidiary Gland Pharma International PTE has entered into an agreement to acquire 100% of France-based contract development…